Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 4/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.37 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.37 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.35 |
| ▸ | SMAD2 | Q15796 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25259131 | 0.81 | SYK (0.44) | TGFBR1MAPK14ACVR1BIDO1 | |
| SCHEMBL30139863 | 0.79 | TGFBR1 (0.64) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL25085252 | 0.79 | TGFBR1 (0.40) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL29832164 | 0.77 | TGFBR1 (0.64) | TGFBR1MAPK14RIPK2ACVR1BMTOR | |
| SCHEMBL23392209 | 0.76 | TGFBR1 (0.39) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL23408398 | 0.75 | TGFBR1 (0.45) | TGFBR1MAPK14MTORIDO1CYP2D6 | |
| SCHEMBL5200100 | 0.75 | IDO1 (0.48) | TGFBR1MAPK14MTORIDO1CYP2D6 | |
| SCHEMBL25842013 | 0.75 | MAPK14 (0.40) | TGFBR1MAPK14IDO1TGFBR2 | |
| SCHEMBL23392190 | 0.74 | TGFBR1 (0.37) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL4488213 | 0.74 | TGFBR1 (0.51) | TGFBR1MAPK14RIPK2ACVR1BMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183220-A1 | HETEROCYCLIC COMPOUND AS INHIBITOR OF CASEIN KINASE 1-DELTA AND/OR ACTIVIN RECEPTOR-LIKE KINASE 5 | ALCHEMEDICINE, INC. (JP) | 2023-06-15 | — | — | US | disclosed |
| US-20230183220-A1 | HETEROCYCLIC COMPOUND AS INHIBITOR OF CASEIN KINASE 1-DELTA AND/OR ACTIVIN RECEPTOR-LIKE KINASE 5 | ALCHEMEDICINE, INC. (JP) | 2023-06-15 | — | — | US | disclosed |
| EP-4174061-A1 | HETEROCYCLIC COMPOUND AS INHIBITOR FOR CASEIN KINASE 1d AND/OR ACTIVIN RECEPTOR-LIKE KINASE 5 | Alchemedicine, Inc. (JP) | 2023-05-03 | — | — | EP | disclosed |
| CN-116034105-A | Heterocyclic compounds as inhibitors of casein kinase 1 delta and/or activin receptor-like kinase 5 | 亚克医药株式会社 | 2023-04-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183220-A1 | HETEROCYCLIC COMPOUND AS INHIBITOR OF CASEIN KINASE 1-DELTA AND/OR ACTIVIN RECEPTOR-LIKE KINASE 5 | CSNK1A1, CSNK1G1, CSNK1D | TGFBR1 109/4885MAPK14 405/4885RIPK2 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.